Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Research Report 2025
Description
Summary
According to APO Research, The global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug include Novartis AG, Pfizer Inc, AstraZeneca Plc, Seattle Genetics Inc, NuvOx Pharma LLC, Modus Therapeutics Holding AB, Gilead Sciences Inc and Bristol-Myers Squibb Company, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug.
The Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Company
Novartis AG
Pfizer Inc
AstraZeneca Plc
Seattle Genetics Inc
NuvOx Pharma LLC
Modus Therapeutics Holding AB
Gilead Sciences Inc
Bristol-Myers Squibb Company
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Type
SGD-2083
Crizanlizumab
PF-04447943
NVX-508
Others
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Application
Clinic
Hospital
Others
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Application
Clinic
Hospital
Others
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
According to APO Research, The global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug include Novartis AG, Pfizer Inc, AstraZeneca Plc, Seattle Genetics Inc, NuvOx Pharma LLC, Modus Therapeutics Holding AB, Gilead Sciences Inc and Bristol-Myers Squibb Company, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug.
The Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Company
Novartis AG
Pfizer Inc
AstraZeneca Plc
Seattle Genetics Inc
NuvOx Pharma LLC
Modus Therapeutics Holding AB
Gilead Sciences Inc
Bristol-Myers Squibb Company
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Type
SGD-2083
Crizanlizumab
PF-04447943
NVX-508
Others
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Application
Clinic
Hospital
Others
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Application
Clinic
Hospital
Others
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Table of Contents
112 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug by Type
- 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
- 2.2.2 SGD-2083
- 2.2.3 Crizanlizumab
- 2.2.4 PF-04447943
- 2.2.5 NVX-508
- 2.2.6 Others
- 2.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug by Application
- 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.3.2 Clinic
- 2.3.3 Hospital
- 2.3.4 Others
- 2.4 Assumptions and Limitations
- 3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Breakdown Data by Type
- 3.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Historic Market Size by Type (2020-2025)
- 3.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Market Size by Type (2026-2031)
- 4 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Breakdown Data by Application
- 4.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Historic Market Size by Application (2020-2025)
- 4.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Market Size by Application (2026-2031)
- 5 Global Growth Trends
- 5.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Perspective (2020-2031)
- 5.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Growth Trends by Region
- 5.2.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region: 2020 VS 2024 VS 2031
- 5.2.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Historic Market Size by Region (2020-2025)
- 5.2.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Market Size by Region (2026-2031)
- 5.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Dynamics
- 5.3.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Trends
- 5.3.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Drivers
- 5.3.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Challenges
- 5.3.4 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players by Revenue
- 6.1.1 Global Top Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players by Revenue (2020-2025)
- 6.1.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Players (2020-2025)
- 6.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Head Office and Area Served
- 6.4 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players, Product Type & Application
- 6.5 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Manufacturers Established Date
- 6.6 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2020-2031)
- 7.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2020-2025)
- 7.4 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
- 8 Europe
- 8.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2020-2031)
- 8.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 8.3 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2020-2025)
- 8.4 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2026-2031)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2020-2031)
- 9.2 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 9.3 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2020-2025)
- 9.4 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2026-2031)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
- 10 South America
- 10.1 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2020-2031)
- 10.2 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 10.3 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2020-2025)
- 10.4 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2026-2031)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
- 11 Middle East & Africa
- 11.1 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2020-2031)
- 11.2 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 11.3 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2020-2025)
- 11.4 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2026-2031)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
- 12 Players Profiled
- 12.1 Novartis AG
- 12.1.1 Novartis AG Company Information
- 12.1.2 Novartis AG Business Overview
- 12.1.3 Novartis AG Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- 12.1.4 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.1.5 Novartis AG Recent Developments
- 12.2 Pfizer Inc
- 12.2.1 Pfizer Inc Company Information
- 12.2.2 Pfizer Inc Business Overview
- 12.2.3 Pfizer Inc Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- 12.2.4 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.2.5 Pfizer Inc Recent Developments
- 12.3 AstraZeneca Plc
- 12.3.1 AstraZeneca Plc Company Information
- 12.3.2 AstraZeneca Plc Business Overview
- 12.3.3 AstraZeneca Plc Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- 12.3.4 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.3.5 AstraZeneca Plc Recent Developments
- 12.4 Seattle Genetics Inc
- 12.4.1 Seattle Genetics Inc Company Information
- 12.4.2 Seattle Genetics Inc Business Overview
- 12.4.3 Seattle Genetics Inc Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- 12.4.4 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.4.5 Seattle Genetics Inc Recent Developments
- 12.5 NuvOx Pharma LLC
- 12.5.1 NuvOx Pharma LLC Company Information
- 12.5.2 NuvOx Pharma LLC Business Overview
- 12.5.3 NuvOx Pharma LLC Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- 12.5.4 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.5.5 NuvOx Pharma LLC Recent Developments
- 12.6 Modus Therapeutics Holding AB
- 12.6.1 Modus Therapeutics Holding AB Company Information
- 12.6.2 Modus Therapeutics Holding AB Business Overview
- 12.6.3 Modus Therapeutics Holding AB Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- 12.6.4 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.6.5 Modus Therapeutics Holding AB Recent Developments
- 12.7 Gilead Sciences Inc
- 12.7.1 Gilead Sciences Inc Company Information
- 12.7.2 Gilead Sciences Inc Business Overview
- 12.7.3 Gilead Sciences Inc Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- 12.7.4 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.7.5 Gilead Sciences Inc Recent Developments
- 12.8 Bristol-Myers Squibb Company
- 12.8.1 Bristol-Myers Squibb Company Company Information
- 12.8.2 Bristol-Myers Squibb Company Business Overview
- 12.8.3 Bristol-Myers Squibb Company Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- 12.8.4 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.8.5 Bristol-Myers Squibb Company Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Type (2020-2025) & (US$ Million)
- Table 6. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2020-2025)
- Table 7. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)
- Table 8. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Type (2026-2031)
- Table 9. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2020-2025) & (US$ Million)
- Table 10. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2020-2025)
- Table 11. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)
- Table 12. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Application (2026-2031)
- Table 13. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 14. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region (2020-2025) & (US$ Million)
- Table 15. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Region (2020-2025)
- Table 16. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)
- Table 17. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Region (2026-2031)
- Table 18. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Trends
- Table 19. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Drivers
- Table 20. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Opportunities and Challenges
- Table 21. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Restraints
- Table 22. Global Top Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players by Revenue (US$ Million) & (2020-2025)
- Table 23. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Players (2020-2025)
- Table 24. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- Table 25. Global Key Players of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug, Headquarters and Area Served
- Table 26. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players, Product Type & Application
- Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 29. Players Mergers & Acquisitions, Expansion Plans
- Table 30. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 31. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2020-2025) & (US$ Million)
- Table 32. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2026-2031) & (US$ Million)
- Table 33. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 34. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2020-2025) & (US$ Million)
- Table 35. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2026-2031) & (US$ Million)
- Table 36. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 37. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region (2020-2025) & (US$ Million)
- Table 38. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2026-2031) & (US$ Million)
- Table 39. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 40. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2020-2025) & (US$ Million)
- Table 41. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2026-2031) & (US$ Million)
- Table 42. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 43. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2020-2025) & (US$ Million)
- Table 44. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2026-2031) & (US$ Million)
- Table 45. Novartis AG Company Information
- Table 46. Novartis AG Business Overview
- Table 47. Novartis AG Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025) & (US$ Million)
- Table 48. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- Table 49. Novartis AG Recent Developments
- Table 50. Pfizer Inc Company Information
- Table 51. Pfizer Inc Business Overview
- Table 52. Pfizer Inc Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025) & (US$ Million)
- Table 53. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- Table 54. Pfizer Inc Recent Developments
- Table 55. AstraZeneca Plc Company Information
- Table 56. AstraZeneca Plc Business Overview
- Table 57. AstraZeneca Plc Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025) & (US$ Million)
- Table 58. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- Table 59. AstraZeneca Plc Recent Developments
- Table 60. Seattle Genetics Inc Company Information
- Table 61. Seattle Genetics Inc Business Overview
- Table 62. Seattle Genetics Inc Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025) & (US$ Million)
- Table 63. Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- Table 64. Seattle Genetics Inc Recent Developments
- Table 65. NuvOx Pharma LLC Company Information
- Table 66. NuvOx Pharma LLC Business Overview
- Table 67. NuvOx Pharma LLC Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025) & (US$ Million)
- Table 68. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- Table 69. NuvOx Pharma LLC Recent Developments
- Table 70. Modus Therapeutics Holding AB Company Information
- Table 71. Modus Therapeutics Holding AB Business Overview
- Table 72. Modus Therapeutics Holding AB Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025) & (US$ Million)
- Table 73. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- Table 74. Modus Therapeutics Holding AB Recent Developments
- Table 75. Gilead Sciences Inc Company Information
- Table 76. Gilead Sciences Inc Business Overview
- Table 77. Gilead Sciences Inc Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025) & (US$ Million)
- Table 78. Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- Table 79. Gilead Sciences Inc Recent Developments
- Table 80. Bristol-Myers Squibb Company Company Information
- Table 81. Bristol-Myers Squibb Company Business Overview
- Table 82. Bristol-Myers Squibb Company Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025) & (US$ Million)
- Table 83. Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- Table 84. Bristol-Myers Squibb Company Recent Developments
- Table 85. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Image
- Figure 5. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size Comparison by Type (2025-2031) & (US$ Million)
- Figure 6. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Type: 2024 VS 2031
- Figure 7. SGD-2083 Product
- Figure 8. Crizanlizumab Product
- Figure 9. PF-04447943 Product
- Figure 10. NVX-508 Product
- Figure 11. Others Product
- Figure 12. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Application (2025-2031) & (US$ Million)
- Figure 13. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Application: 2024 VS 2031
- Figure 14. Clinic Product
- Figure 15. Hospital Product
- Figure 16. Others Product
- Figure 17. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (US$ Million), Year-over-Year: 2020-2031
- Figure 18. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031
- Figure 19. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Region: 2024 VS 2031
- Figure 20. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Players in 2024
- Figure 21. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Manufacturers Established Date
- Figure 22. Global Top 5 and 10 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players Market Share by Revenue in 2024
- Figure 23. Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 24. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 25. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2020-2031)
- Figure 26. United States Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 27. Canada Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 28. Mexico Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2020-2031)
- Figure 29. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 30. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2020-2031)
- Figure 31. Germany Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 32. France Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 33. U.K. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 34. Italy Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 35. Spain Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 36. Russia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 37. Netherlands Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 38. Nordic Countries Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 39. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 40. Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2020-2031)
- Figure 41. China Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 42. Japan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 43. South Korea Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 44. India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 45. India Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2020-2031)
- Figure 46. Australia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 47. China Taiwan Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 48. Southeast Asia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 49. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 50. South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Share by Country (2020-2031)
- Figure 51. Brazil Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 52. Argentina Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 53. Chile Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 54. Colombia Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 55. Peru Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size YoY Growth (2020-2031) & (US$ Million)
- Figure 56. Novartis AG Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- Figure 57. Pfizer Inc Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- Figure 58. AstraZeneca Plc Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- Figure 59. Seattle Genetics Inc Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- Figure 60. NuvOx Pharma LLC Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- Figure 61. Modus Therapeutics Holding AB Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- Figure 62. Gilead Sciences Inc Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
- Figure 63. Bristol-Myers Squibb Company Revenue Growth Rate in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2020-2025)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


